MUDr. Pavel Ryšánek, Ph.D.
· Born in Prague, Czech Republic
· Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Albertov 4, 128 00, Prague, Czech Republic
· Tel.: +420 224 968 104, email: pavel.rysanek@lf1.cuni.cz
· ORCID ID: 0000-0001-6727-1663
Researcher ID: AAW-6497-2020
Scopus: 57209051676
Research focus:
· Pharmacokinetics in animal models with special focus on lymphatic transport of drugs after oral administration
· Development of novel lymph-targeting drugs and drug formulations
Education:
· 2018-2023 Ph.D., Pharmacology and toxicology, First Faculty of Medicine, Charles University in Prague, Thesis: Physiological and pathological factors affecting the absorption of drugs
· 2005-2012 doctor of medicine, First Faculty of Medicine, Charles University in Prague
Professional membership:
· Member of the Czech Society for Experimental and Clinical Pharmacology and Toxicology
Awards:
· Best publication in the category experimental pharmacology in 2021 (Czech Society for Experimental and Clinical Pharmacology and Toxicology)
· Best student publication at the First Faculty of Medicine in 2021 (Scientia Foundation)
Publications (selected): see List of Publications
· Pozniak J, Ryšánek P, Smrčka D, Kozlík P, Křížek T, Šmardová J, Nováková A, Das D, Bobek D, Arora M, Hofmann J, Doušová T, Šíma M, Slanař O. Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats. Front Pharmacol. 2024 Feb 20;15:1331637. doi: 10.3389/fphar.2024.1331637. PMID: 38444938; PMCID: PMC10912587.
· Hofmann J, Bartůněk A, Hauser T, Sedmak G, Beránek J, Ryšánek P, Šíma M, Slanař O. Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans. Leukemia. 2023 Dec;37(12):2486-2492. doi: 10.1038/s41375-023-02045-1. Epub 2023 Oct 3. PMID: 37789147; PMCID: PMC10681895.
· Šalamúnová P, Krejčí T, Ryšánek P, Saloň I, Kroupová J, Hubatová-Vacková A, Petřík J, Grus T, Lukáč P, Kozlík P, Křížek T, Dammer O, Beránek J, Šíma M, Slanař O, Štěpánek F. Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os. Int J Pharm. 2023 Jan 21;634:122627. doi: 10.1016/j.ijpharm.2023.122627. Epub ahead of print. PMID: 36693484.
· Ryšánek P, Grus T, Lukáč P, Kozlík P, Křížek T, Pozniak J, Roušarová J, Královičová J, Kutinová Canová N, Boleslavská T, Bosák J, Štěpánek F, Šíma M, Slanař O. Validity of cycloheximide chylomicron flow blocking method for the evaluation of lymphatic transport of drugs. Br J Pharmacol. 2021 Dec;178(23):4663-4674. doi: 10.1111/bph.15644. Epub 2021 Sep 10. PMID: 34365639.
· Ryšánek P, Grus T, Šíma M, Slanař O. Lymphatic Transport of Drugs after Intestinal Absorption: Impact of Drug Formulation and Physicochemical Properties. Pharm Res. 2020 Aug 7;37(9):166. doi: 10.1007/s11095-020-02858-0. PMID: 32770268.